Clinical Spectrum and Outcomes in Hypertrophic Cardiomyopathy With Apical Aneurysms
BACKGROUND: Apical aneurysms in hypertrophic cardiomyopathy (HCM) have been linked to sudden cardiac death (SCD) and a nidus for thromboembolism. Uncertainty remains regarding the level of risk and significance of aneurysm size. OBJECTIVES: The objective of the study was to determine the rate of SCD events and prevalence of apical thrombus or embolic events by size (maximum transverse dimension). METHODS: Apical aneurysms were identified in 510 patients from 10 centers, followed a median of 4.1 years for SCD events (SCD, appropriate implantable cardioverter defibrillator therapy, and resuscitated SCD) or development of apical thrombus/thromboembolism. Relationship between size and SCD events was analyzed using multivariable Cox proportional hazard models. RESULTS: In 510 HCM patients: 19% had small aneurysms (<10 mm), 39% medium (10-19 mm), 39% large (20-39 mm), and 3% very large (≥40 mm). SCD event rate was 2.1%/year, with risk increasing with increasing aneurysm size: 0.2%/year in small, 2.3%/year in medium, 3.0%/year in large and 8.2%/year in very large (P < 0.001). On multivariable analysis, greater size was associated with SCD events, independent of other risk markers or European Society of Cardiology-SCD score. Either an embolic event (3.6% of patients) or apical thrombus (10% of patients) occurred in 13% of patients and was independently associated with greater aneurysm size, 3% in small to 25% in very large aneurysms (P < 0.001). CONCLUSIONS: In a large cohort of HCM patients with apical aneurysms, rates of SCD events were high, with continuous relationship between size and risk. Small aneurysms (<10 mm) were associated with low risk for SCD events (0.2%/year), whereas aneurysms ≥10 mm with high risk (>2%/year). Although embolic events were uncommon, increasing aneurysm size was associated with the prevalence of apical thrombi.
Authors
- Arnon Adler (ORCID: https://orcid.org/0000-0001-8142-4013)
- Daniele Massera (ORCID: https://orcid.org/0000-0002-9499-6456)
- Liza Chacko (ORCID: https://orcid.org/0000-0002-4524-1436)
- Iacopo Olivotto (ORCID: https://orcid.org/0000-0003-1751-9266)
- Alfred Albano (ORCID: https://orcid.org/0000-0002-9505-1657)
- Chiara Zocchi (ORCID: https://orcid.org/0000-0002-6406-4674)
- Hisham Ahamed (ORCID: https://orcid.org/0000-0002-1740-8948)
- Mark V. Sherrid (ORCID: https://orcid.org/0000-0003-4972-7780)
- Michael A. Fifer (ORCID: https://orcid.org/0000-0002-8363-445X)
- Deacon Lee (ORCID: https://orcid.org/0000-0002-0090-5403)
- Richard Carrick (ORCID: https://orcid.org/0000-0001-5589-1216)
- Aparna Hari
- Jose Madrazo
- Christopher Madias
- Nadia Bokhari
- Amanda M. Varnava
- Barry J. Maron
- Raymond H. Chan
- Martin S. Maron
- Albree F. Tower-Rader
- Ethan J. Rowin
- Harry Rakowski
Institutions
- Amrita Institute of Medical Sciences and Research Centre (IN)
- Lahey Hospital and Medical Center (US)
- Tufts Medical Center (US)
- University Health Network (CA)
- Johns Hopkins University (US)
- Spectrum Health (US)
- Johns Hopkins Medicine (US)
- Massachusetts General Hospital (US)
- Corewell Health Blodgett Hospital (US)
- Lahey Medical Center (US)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Diabetes & Endocrine Associates (US)
- University of Florence (IT)
- Imperial College London (GB)
Publication Details
- Journal
- JACC Advances
- Published
- 2026-06-17
- DOI
- https://doi.org/10.1016/j.jacadv.2026.102919
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00